3Mark H. Whiteford M.D.,Heather M. Whiteford M.D.,Laurence F. Yee M.D.,Olagunju A. Ogunbiyi M.D.,Farrokh Dehdashti M.D.,Barry A. Siegel M.D.,Elisa H. Birnbaum M.D.,James W. Fleshman M.D.,Ira J. Kodner M.D.,Dr. Thomas E. Read M.D..Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum[J]. Diseases of the Colon & Rectum . 2000 (6)
4Curlei SA.Outcomes after surgical treatment of colorectal cancerliver metastases. Seminars in Oncology . 2005
5Ito K,,Hibi K,Ando H,et al.Usefulness of analytical CEA doubling time and hife-life time foroverlooked synchronous metastases in colorectal carcino-ma. Japanese Journal of Clinical Oncology . 2002
6Ruers T,Bleichrodt RP.Treatment of liver metastases, an update on the possibilities and results. European Journal of Cancer . 2002
7Wanebo HJ,Chu QD,Wezeridis MP,et al.Patient selection for hepatic resection of colorectal metastases. Archives of Surgery . 1996
3KEMENY N. Presurgical chemotherapy in patients being considered for liver resection[J]. Oncolologist, 2007,12(7) :825- 839.
4秦新裕.结直肠癌肝转移的综合治疗进展[C].全国肿瘤转移学会大会论文集,2007:7-8.
5GREGORY D L, BARUCH B, NACY E K. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from eoloreetal earcinoma[J]. J Clin Oncol, 2005,23(9):2038-2048.
6CAPUSSOTTI L, FERRERO A, VIGANO L, et al. Major liver resections synchronous with colorectal surgery[J]. Ann Surg Oneol, 2007,14(1) :195-201.
7MALIK H Z, HAMADY Z Z, ADAIR R, et al. Prognostic influence of multiple hepatic metastases from colorectal cancer [J]. Eur J Surg Oncol, 2007,33 (4) :468-473.
8Pawlik TM, Choti MA. Surgical therapy for colorectal metas- tases to the liver[J].Journal of Gastrointestinal Surgery, 2007, 11(8): 1057-1077.
9Duffy M J, van Dalen A, Haglund C, et al. Tumour markers in eoloreetal Cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use[J].Cancer, 2007, 43(9): 1348-1360.
10Ychou M, Viret F, Kramar A, et al. Tritherapy with fluo- rouraeil/leucovorin, irinotecan and oxaliplatin (FOLFIRI- NOX): a phase II study in eoloreetal Cancer patients with non-resectable liver metastases[J].Cancer Chemother Phar- maeol, 2008, 62(2): 195-201.
